Src family kinases mediate betel quid-induced oral cancer cell motility and could be a biomarker for early invasion in oral squamous cell carcinoma

Neoplasia

Volumn 10, Issue 12, 2008, Pages 1393-1401

  Chen, Jeff Yi Fu ^a   Hung, Chih Chang ^a   Huang, Kai Lieh ^b   Chen, Yi Ting ^a   Liu, Shyun Yeu ^c,d   Chiang, Wei Fan ^c   Chen, Hau Ren ^e   Yen, Ching Yu ^c   Wu, Yu Jen ^f   Ko, Jenq Yuh ^g,h   Jou, Yuh Shan ^b,i  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^f MEIHO UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h NONE   (Taiwan)

ⁱ ACADEMIA SINICA   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN KINASE FYN; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ARTICLE; BETEL NUT; CANCER CELL; CANCER INVASION; CATALYSIS; CELL ACTIVITY; CELL MIGRATION; CELL MOTILITY; EMBRYO; ENZYME LOCALIZATION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MASTICATION; MOUSE; MOUTH CARCINOMA; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; WILD TYPE;

EID: 57349168459     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08854     Document Type: Article

References (37)

1. Sharan RN (1996). Association of betel nut with carcinogenesis. Cancer J 9, 13-19.
2. Kwan HW (1976). A statistical study on oral carcinoma in Taiwan with emphasis on the relationship with betel nut chewing: a preliminary report. Taiwan Yi Xue Hui Za Zhi 75, 497-505.
3. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, and Tsai CC (1995). Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 24, 450-453.
4. Bhide SV, Shivapurkar NM, Gothoskar SV, and Ranadive KJ (1979). Carcinogenicity of betel quid ingredients: feeding mice with aqueous extract and the polyphenol fraction of betel nut. Br J Cancer 40, 922-926.
5. Jeng JH, Chang MC, and Hahn LJ (2001). Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol 37, 477-492.
6. IARC (2003). Betel-quid and areca nut chewing and some areca nut-related nitrosamines. IARC Monogr Eval Carcinog Risk Chem Hum 85, 11-18.
7. Sundqvist K and Grafstrom RC (1992). Effects of areca nut on growth, differentiation and formation of DNA damage in cultured human buccal epithelial cells. Int J Cancer 52, 305-310.
8. Jeng JH, Hahn LJ, Lin BR, Hsieh CC, Chan CP, and Chang MC (1999). Effects of areca nut, inflorescence Piper betle extracts and arecoline on cytotoxicity, total and unscheduled DNA synthesis in cultured gingival keratinocytes. J Oral Pathol Med 28, 64-71.
9. Lai KC and Lee TC (2006). Genetic damage in cultured human keratinocytes stressed by long-term exposure to areca nut extracts. Mutat Res 599, 66-75.
10. Chang MC, Ho YS, Lee PH, Chan CP, Lee JJ, Hahn LJ, Wang YJ, and Jeng JH (2001). Areca nut extract and arecoline induced the cell cycle arrest but not apoptosis of cultured oral KB epithelial cells: association of glutathione, reactive oxygen species and mitochondrial membrane potential. Carcinogenesis 22, 1527-1535.
11. Jeng JH, Wang YJ, Chiang BL, Lee PH, Chan CP, Ho YS, Wang TM, Lee JJ, Hahn LJ, and Chang MC (2003). Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E2, interleukin-6 and TNF-alpha production of oral epithelial cells by areca nut extract and arecoline. Carcinogenesis 24, 1301-1315.
12. 2 production, interleukin-6 production, cell cycle arrest, and cytotoxicity in primary oral keratinocytes and KB cancer cells by areca nut ingredients is differentially regulated by MEK/ERK activation. J Biol Chem 279, 50676-50683.
13. Lin SC, Lu SY, Lee SY, Lin CY, Chen CH, and Chang KW (2005). Areca (betel) nut extract activates mitogen-activated protein kinases and NF-kappaB in oral keratinocytes. Int J Cancer 116, 526-535.
14. Regezi JA, Sciubba JJ, and Jordan RCK (Eds.) (1989). Oral Pathology: Clinical-Pathologic Correlations. Philadelphia, PA: WB Saunders Company, pp. 70-83.
15. Coussens LM and Werb Z (1996). Matrix metalloproteinases and the development of cancer. Chem Biol 3, 895-904.
16. Shinohara M, Hiraki A, and Ikebe T (1998). Immunohistochemical study of desmosomes in oral squamous cell carcinoma: correlation with cytokeratin and E-cadherin staining, and with tumor behavior. J Pathol 184, 369-381.
17. Kudo Y, Kitajima S, Ogawa I, Hiraoka M, Sargolzaei S, Keikhaee MZ, Sato S, Miyauchi M, and Takata T (2004). Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous β-catenin. Clin Cancer Res 10, 5455-5463.
18. Saussez S, Camby I, Toubeau G, and Kiss R (2007). Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. Head Neck 29, 874-884.
19. Demers M, Magnaldo T, and St-Pierre Y (2005). A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression. Cancer Res 65, 5205-5210.
20. Shintani S, Li C, Mihara M, Nakashiro K, and Hamakawa H (2003). Gefitinib ("Iressa"), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. Cancer Lett 201, 149-155.
21. Chen JYF, Chang YL, Yu YJ, Chao CC, Kao HW, Wu CT, Lin WC, Ko JY, and Jou YS (2004). Specific induction of the high-molecular-weight microtubule- associated protein 2 (hmw-MAP2) by betel quid extract in cultured oral keratinocytes: clinical implications in betel quid-associated oral squamous cell carcinoma (OSCC). Carcinogenesis 25, 269-276.
22. Chan PC, Chen YL, Cheng CH, Yu KC, Cary LA, Shu KH, Ho WL, and Chen HC (2003). Src phosphorylates Grb2-associated binder 1 upon hepatocyte growth factor stimulation. J Biol Chem 278, 44075-44082.
23. Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, Berkowitz RS, and Mok SC (2000). Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 156, 409-417.
24. Calalb MB, Polte TR, and Hanks SK (1995). Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 15, 954-963.
25. Parsons SJ and Parsons JT (2004). Src family kinases, key regulator of signal transduction. Oncogene 23, 7906-7909.
26. Playford MP and Schaller MD (2004). The interplay between Src and integrins in normal and tumor biology. Oncogene 23, 7928-7946.
27. Frame MC (2002). Src in cancer: deregulation and consequences for cell behavior. Biochim Biophys Acta 1602, 114-130.
28. Ishizawar R and Parsons SJ (2004). c-Src and cooperating partners in human cancer. Cancer Cell 6, 209-214.
29. Summy JM and Gallick GE (2003). Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22, 337-358.
30. Cartwright CA, Coad CA, and Egbert J (1994). Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J Clin Invest 93, 509-515.
31. Biscardi JS, Tice DA, and Parsons SJ (1999). c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res 76, 61-119.
32. Egloff AM and Grandis JR (2008). Targeting epidermal growth factor receptor and Src pathways in head and neck cancer. Semin Oncol 35, 286-297.
33. 4 promotes migration, invasion through Tiam1 upregulation, and subsequent Rac activation. Neoplasia 10, 408-417.
34. 1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 10, 797-803.
35. Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, and Chellappans S (2006). Nicotine induces cell proliferation by β-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 116, 2208-2217.
36. Klber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, et al. (2008). Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13, 235-248.
37. Decaestecker C, Debeir O, van Ham P, and Kiss R (2007). Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev 27, 149-176.